Research and Markets: US: Healthcare Reform, Intellectual Property and Regulatory Update

DUBLIN--(BUSINESS WIRE)-- Research and Markets(http://www.researchandmarkets.com/research/c6b929/us_healthcare_ref) has announced the addition of the "US: Healthcare Reform, Intellectual Property and Regulatory Update" report to their offering.

The US FDA continues to work towards improving its reputation, through addressing unmet public health needs, improving supply chain security, as well as providing greater transparency to the public and pharma in order to reduce regulatory uncertainty. However, plans to tighten compliance activities could be regarded as a potentially new burden to pharma in terms of time and cost.

Highlights

• In a positive development for branded pharma, the patent reform bill was passed in September 2011 in a move designed to help curb the rising level of patent litigation and help clear a backlog of patent applications. However, small pharma and generics companies are concerned about it could ultimately delay access to generic medicines.
• The constitutionality of the healthcare reform law hangs in the balance, the debate on biologic exclusivity periods has yet to reach an outcome, and pharma is concerned about the substantial savings that are expected to be made to the Medicare and Medicaid insurance systems.
• Proposals to increase the powers of the Independent Payment Advisory Board could spell further concern for the pharma industry.

Key Topics Covered:

• Executive Summary
• Introduction
• Healthcare Reform Update
• Regulatory Issues Update
• Intellectual Property Update
• Bibliography

For more information visit http://www.researchandmarkets.com/research/c6b929/us_healthcare_ref

Research and Markets Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Source: Research and Markets